Prademagene zamikeracel is a gene therapy used to treat wounds associated with recessive dystrophic epidermolysis bullosa. Prademagene zamikeracel is a sheet-based gene therapy comprising autologous cells isolated from skin punch biopsies of patients with mutations in the collagen type VII alpha 1 chain (COL7A1) gene.
- Mechanism
- Curator reviewed · 6 references
RDEB is a skin disorder caused by mutations in the COL7A1 gene, which encodes for type VII collagen (C7) - a protein crucial for dermal-epidermal adhesion and integrity. C7 is the primary component of anchoring fibrils (AF) that form the connection between epidermis and the dermis; therefore, low or absent C7 can cause disrupted keratinocyte adhesion, reduced mucocutaneous mechanical stability, and skin fragility. These effects lead to the signs and symptoms of RDEB, such as excessive blisters and wounds.
Prademagene zamikeracel topical therapy consists of a patient's own keratinocytes that have been genetically modified through RVV transduction to express the COL7A1 gene to produce the C7 protein. These cells are formed into cellular sheets for topical application onto wounds.
- Primary indication
- Prademagene zamikeracel is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).Curator reviewed · 1 structured indication
- First approval
- United States, 2025
- Also known as
- Ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the COL7A1 gene
- Code names
- EB-101
- Brand names
Resolves to
What you can answer from here — as of July 12, 2026
Which drugs share a target with Prademagene zamikeracel, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account